Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) has provided an announcement.
Race Oncology Ltd has announced its 2025 Annual General Meeting, scheduled for November 24, 2025, at the State Library NSW in Sydney. The company has provided shareholders with a letter, notice of the meeting, and proxy form, emphasizing the importance of shareholder engagement and participation. This meeting is a key event for stakeholders to discuss the company’s strategic direction and operational updates.
More about Race Oncology Ltd.
Race Oncology Ltd is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, RCDS1, is a small molecule anticancer agent targeting cancer growth regulator MYC. The company is developing a proprietary formulation, RC220, for multiple oncology indications and exploring partnerships to enhance global patient access.
Average Trading Volume: 450,620
Technical Sentiment Signal: Buy
Current Market Cap: A$724M
See more data about RAC stock on TipRanks’ Stock Analysis page.